Overview

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Status:
Recruiting
Trial end date:
2025-07-15
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse ITP
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Friendship Hospital
Beijing Hospital
Beijing Luhe Hospital
Beijing Tsinghua Changgeng Hospital
China-Japan Friendship Hospital
Chinese PLA General Hospital
Navy General Hospital, Beijing
Peking University First Hospital
Peking University Third Hospital
Treatments:
Danazol
Teriflunomide